Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis

The rate of disease progression in amyotrophic lateral sclerosis (ALS) is highly variable, even between patients with the same genetic mutations. Metabolic alterations may affect disease course variability in ALS patients, but challenges in identifying the preclinical and early phases of the disease...

Full description

Bibliographic Details
Main Authors: Gabriel N. Valbuena, Lavinia Cantoni, Massimo Tortarolo, Caterina Bendotti, Hector C. Keun
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2019.01276/full
id doaj-3925755a4d7840dd8b28310ab6be4296
record_format Article
spelling doaj-3925755a4d7840dd8b28310ab6be42962020-11-25T02:07:52ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2019-12-011310.3389/fnins.2019.01276486529Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral SclerosisGabriel N. Valbuena0Lavinia Cantoni1Massimo Tortarolo2Caterina Bendotti3Hector C. Keun4Department of Surgery and Cancer, Imperial College London, London, United KingdomDepartment of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, ItalyDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, ItalyDepartment of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, ItalyDepartment of Surgery and Cancer, Imperial College London, London, United KingdomThe rate of disease progression in amyotrophic lateral sclerosis (ALS) is highly variable, even between patients with the same genetic mutations. Metabolic alterations may affect disease course variability in ALS patients, but challenges in identifying the preclinical and early phases of the disease limit our understanding of molecular mechanisms underlying differences in the rate of disease progression. We examined effects of SOD1G93A on thoracic and lumbar spinal cord metabolites in two mouse ALS models with different rates of disease progression: the transgenic SOD1G93A-C57BL/6JOlaHsd (C57-G93A, slow progression) and transgenic SOD1G93A-129SvHsd (129S-G93A, fast progression) strains. Samples from three timepoints (presymptomatic, disease onset, and late stage disease) were analyzed using Gas Chromatography-Mass Spectrometry metabolomics. Tissue metabolome differences in the lumbar spinal cord were driven primarily by mouse genetic background, although larger responses were observed in metabolic trajectories after the onset of symptoms. The significantly affected lumbar spinal cord metabolites were involved in energy and lipid metabolism. In the thoracic spinal cord, metabolic differences related to genetic background, background-SOD1 genotype interactions, and longitudinal SOD1G93A effects. The largest responses in thoracic spinal cord metabolic trajectories related to SOD1G93A effects before onset of visible symptoms. More metabolites were significantly affected in the thoracic segment, which were involved in energy homeostasis, neurotransmitter synthesis and utilization, and the oxidative stress response. We find evidence that initial metabolic alterations in SOD1G93A mice confer disadvantages for maintaining neuronal viability under ALS-related stressors, with slow-progressing C57-G93A mice potentially having more favorable spinal cord bioenergetic profiles than 129S-G93A. These genetic background-associated metabolic differences together with the different early metabolic responses underscore the need to better characterize the impact of germline genetic variation on cellular responses to ALS gene mutations both before and after the onset of symptoms in order to understand their impact on disease development.https://www.frontiersin.org/article/10.3389/fnins.2019.01276/fullamyotrophic lateral sclerosis (ALS)SOD1G93A ALS mouse modelmetabolismmetabolomicsspinal cordoxidative stress
collection DOAJ
language English
format Article
sources DOAJ
author Gabriel N. Valbuena
Lavinia Cantoni
Massimo Tortarolo
Caterina Bendotti
Hector C. Keun
spellingShingle Gabriel N. Valbuena
Lavinia Cantoni
Massimo Tortarolo
Caterina Bendotti
Hector C. Keun
Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
Frontiers in Neuroscience
amyotrophic lateral sclerosis (ALS)
SOD1G93A ALS mouse model
metabolism
metabolomics
spinal cord
oxidative stress
author_facet Gabriel N. Valbuena
Lavinia Cantoni
Massimo Tortarolo
Caterina Bendotti
Hector C. Keun
author_sort Gabriel N. Valbuena
title Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
title_short Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
title_full Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
title_fullStr Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
title_full_unstemmed Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis
title_sort spinal cord metabolic signatures in models of fast- and slow-progressing sod1g93a amyotrophic lateral sclerosis
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2019-12-01
description The rate of disease progression in amyotrophic lateral sclerosis (ALS) is highly variable, even between patients with the same genetic mutations. Metabolic alterations may affect disease course variability in ALS patients, but challenges in identifying the preclinical and early phases of the disease limit our understanding of molecular mechanisms underlying differences in the rate of disease progression. We examined effects of SOD1G93A on thoracic and lumbar spinal cord metabolites in two mouse ALS models with different rates of disease progression: the transgenic SOD1G93A-C57BL/6JOlaHsd (C57-G93A, slow progression) and transgenic SOD1G93A-129SvHsd (129S-G93A, fast progression) strains. Samples from three timepoints (presymptomatic, disease onset, and late stage disease) were analyzed using Gas Chromatography-Mass Spectrometry metabolomics. Tissue metabolome differences in the lumbar spinal cord were driven primarily by mouse genetic background, although larger responses were observed in metabolic trajectories after the onset of symptoms. The significantly affected lumbar spinal cord metabolites were involved in energy and lipid metabolism. In the thoracic spinal cord, metabolic differences related to genetic background, background-SOD1 genotype interactions, and longitudinal SOD1G93A effects. The largest responses in thoracic spinal cord metabolic trajectories related to SOD1G93A effects before onset of visible symptoms. More metabolites were significantly affected in the thoracic segment, which were involved in energy homeostasis, neurotransmitter synthesis and utilization, and the oxidative stress response. We find evidence that initial metabolic alterations in SOD1G93A mice confer disadvantages for maintaining neuronal viability under ALS-related stressors, with slow-progressing C57-G93A mice potentially having more favorable spinal cord bioenergetic profiles than 129S-G93A. These genetic background-associated metabolic differences together with the different early metabolic responses underscore the need to better characterize the impact of germline genetic variation on cellular responses to ALS gene mutations both before and after the onset of symptoms in order to understand their impact on disease development.
topic amyotrophic lateral sclerosis (ALS)
SOD1G93A ALS mouse model
metabolism
metabolomics
spinal cord
oxidative stress
url https://www.frontiersin.org/article/10.3389/fnins.2019.01276/full
work_keys_str_mv AT gabrielnvalbuena spinalcordmetabolicsignaturesinmodelsoffastandslowprogressingsod1g93aamyotrophiclateralsclerosis
AT laviniacantoni spinalcordmetabolicsignaturesinmodelsoffastandslowprogressingsod1g93aamyotrophiclateralsclerosis
AT massimotortarolo spinalcordmetabolicsignaturesinmodelsoffastandslowprogressingsod1g93aamyotrophiclateralsclerosis
AT caterinabendotti spinalcordmetabolicsignaturesinmodelsoffastandslowprogressingsod1g93aamyotrophiclateralsclerosis
AT hectorckeun spinalcordmetabolicsignaturesinmodelsoffastandslowprogressingsod1g93aamyotrophiclateralsclerosis
_version_ 1724929179226472448